Research Article
Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy
Table 2
First-line chemotherapeutic regimens.
| First-line chemotherapy | (%) | Before pemetrexed approval | After pemetrexed approval |
| Platinum-based chemotherapy with pemetrexed | 43 (30.9%) | 0 | 43 | Cisplatin/doxorubicin with or without tamoxifen | 32 (23.0%) | 32 | 0 | Platinum-based chemotherapy with gemcitabine | 18 (12.9%) | 15 | 3 | Gemcitabine | 15 (10.8%) | 15 | 0 | Gefitinib | 10 (7.2%) | 0 | 10 | Other regimens (each regimen representing <5%) | 21 (15.1%) | 10 | 11 |
|
|